Journals / Anatolian Current Medical Journal / 2023 / Cilt: 5 Sayı: 4

Nitric oxide therapy in COVID-19 patients with acute respiratory distress in intensive care unit

Pages
339–344
Publication Date
2023-10-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the effective dose and safety of iNO is still not clear.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Administration of inhaled nitric oxide (iNO) is a promising, new, non-standard approach to directly treat viral load while increasing oxygenation.
📊
Key Findings & Data:The aim of this research was to elucidate the clinical and laboratory response to the treatment of the patients who were diagnosed with COVID-19 in the intensive care unit (İCU) and followed-up due to respiratory failure and given iNO.
💡
Conclusion & Impact:However, the effective dose and safety of iNO is still not clear.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Nitric oxide · inhaled nitric oxide · acute respiratory distress syndrome

Abstract

Objective: Administration of inhaled nitric oxide (iNO) is a promising, new, non-standard approach to directly treat viral load while increasing oxygenation. The aim of this research was to elucidate the clinical and laboratory response to the treatment of the patients who were diagnosed with COVID-19 in the intensive care unit (İCU) and followed-up due to respiratory failure and given iNO. Materials & Method: A total of 46 individuals who were diagnosed with COVID-19 and developed severe respiratory failure, were followed up with or without intubation, had previously received anti-cytokine therapy, and tried prone position were evaluated within the scope of the study. The time to start iNO treatment in the İCU, if iNO was applied after RT-PCR positivity, whether iNO was given with or without intubation were obtained from hospital records. Results: A statistically significant difference has been achieved in arterial partial pressure of oxygen (PaO2), peripheral oxygen saturation (SpO2) and ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FİO2) ratios before and after iNO (p<0.05). There were increases after iNO initiation compared to before iNO in all laboratory parameters with significant differences. It was determined that the iNO onset times of deceased patients were significantly delayed. The relationship between the duration of mechanical ventilation, the duration of stay in the İCU, and the onset of iNO was statistically significant relationship between all measurements (p<0.05). Conclusion: iNO has been suggested as an alternative rescue methodbefore invasive treatment, especially for the relief of hypoxemia. However, the effective dose and safety of iNO is still not clear.

🔖

Cite This Article

SEĞMEN, F., ÇALILI, D. K., ALP, G., BÖLÜKBAŞI, D., MISIR, H. D., UYSAL, E., DEMİR, N., ERDEM, D. (2023). Nitric oxide therapy in COVID-19 patients with acute respiratory distress in intensive care unit. Anatolian Current Medical Journal, Cilt: 5 Sayı: 4, 339–344. https://ajindex.com/articles/968501

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Erdogan C, Kılınc M, Tanrıverdi SY, Sungurtekin H. Spontaneous Pneumothorax and Pneumomediastinum in COVID-19 Pneumonia. J Crit Intens Care. 2022;13(2):79-83.
  2. Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020; 96:403-407
  3. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
  4. Dalan R, Bornstein SR, El-Armouche A, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020;52(5):257-263.
  5. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir Med. 2021;176:106239. Force A.D.T. Acute respiratory distress syndrome: the Berlin Definition. J Am Med Assoc. 2012;307(23):2526–2533.
  6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;28:1054-1062
  7. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315:788–800.
  8. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;1;180(7):934-943.
  9. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;6:CD002787. Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9:69. Feng W-X, Yang Y, Wen J, Liu Y-X, Liu L, Feng C. Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension. ESC Heart Fail. 2021;8:714–718.
  10. Kobayashi J, Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann Intensive Care. 2020;10:61. Parikh R, Wilson C, Weinberg J, Gavin D, Murphy J, Reardon CC. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther Adv Respir Dis. 2020;14:1753466620933510. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
  11. Ignarro LJ, Buga GM, Wood KS, R E Byrns, G Chaudhuri. Endothelium-derived relaxing factor pro